Bacterial and fungal infections remain a significant cause of transplant-related mortality following allogeneic stem cell transplantation (SCT). Granulocyte transfusions (GTs) may reduce the neutropenic period after SCT and prevent further progression of the existing infection (that is, therapeutic GT) in addition to standard antibacterial and antifungal therapy. A retrospective analysis was performed on 28 consecutive pediatric SCT recipients who received at least one dose of GT between March 2003 and November 2013 at a single institution. All donors were conditioned with G-CSF+dexamethasone with harvest performed 12-18 h later. Indications for SCT were acute leukemia in 46% (13/28) and severe aplastic anemia in 21% (6/28). The main indications for GT were invasive fungal disease in 50%, bacterial infection in 21% and co-morbidities with predicted reduced tolerance to sepsis in 18% (5/28). The median number of GT was 6 (range 1-14) with a median dose of 3.56 × 10 10 granulocytes infused. The median increment in ANC was 1.06 × 10 9 /L and correlated with the granulocyte dose infused. Adverse reactions observed were mild and infrequent. Sixty-four percent of patients (18/28) are alive with only 2 of the 10 deaths being related to progression of infection. In addition there was a low overall incidence of grade 3-4 acute mucositis and a very low incidence (7%) of acute GvHD grade 3-4. Single-donor GTs afford protection to children undergoing SCT at additional risk of infection and may reduce the overall incidence of severe GvHD.
INTRODUCTION
Infection associated with chemotherapy-induced neutropenia remains one of the major causes of allogeneic stem cell transplantation (SCT)-related morbidity and mortality. In some patients infections progress despite improved supportive care with broad-spectrum antibacterial and antifungal agents. Patients who are considered for allogeneic SCT and have pre-existing infections, carry an additional mortality risk. 1 Therapeutic transfusions of granulocytes from healthy donors have been used since 1970. However, demonstration of clinical benefit to patients has been inconsistent. The reasons for this include variable granulocyte doses, variable collection techniques and significant side effects, notably pulmonary infiltrates. In the late 1970s, three randomized controlled studies in infected neutropenic patients evaluated the response to treatment with antibiotics with or without theraupeutic granulocyte transfusions (GTs). The survival rate was higher in patients who received higher doses of granulocytes (41.7 × 10 10 /dose), [2] [3] [4] this was confirmed by later reports. [5] [6] [7] [8] In studies of neonatal sepsis there was a survival benefit from using granulocytes obtained from centrifugation leukapheresis as opposed to buffy coat separation owing to a significantly higher dose obtained in the leukapheresis product. 9, 10 Granulocyte donors mobilized with G-CSF and dexamethasone produced significantly higher yields of granulocytes. 5, 7, 11 Some studies concluded that bacterial infections responded well to the treatment with GTs but serious/invasive fungal infections with tissue damage responded poorly. 3, 5, 6, 9, 12 The timing and rate of GTs had a role, with early and more frequent administration of GTs leading to improved outcomes. 13, 14 One of the significant drawbacks in early studies was the significant side effects observed in recipients. Some studies have confirmed the decreased risk of adverse reactions and increased efficacy of GTs partially matched for HLA antigens and ABO groups. 6, 15 Van de Watering et al. 16 reported reduction of severe pulmonary toxicity after the introduction of the leukapheresis method for granulocyte collection.
Few reports have been published on the efficacy of prophylactic GTs. A Cochrane review in 2009 by Massey et al. 13 concluded that higher doses of prophylactic GTs reduced the risk of mortality from infection. Adkins et al. 15, 17 demonstrated some clinical benefits from prophylactic GTs if given daily and when no leukocyte antibodies were present in the recipients. Kerr et al.
11
used prophylactic GTs for eight patients with high risk of invasive fungal disease (IFD) in the allogeneic transplant setting and showed safety and efficacy of that approach.
In this article we have examined the impact of GTs in a high-risk group of pediatric patients undergoing allogeneic SCT with concomitant infections and/or other significant co-morbidities at a single institution.
MATERIALS AND METHODS Patients
Between April 2003 and November 2013, 28 consecutive patients who received at least one dose of GT were included in the study. Patient characteristics are summarized in Table 1 . Patients received a total of 145 GTs. The median age was 6.5 years (range 3.5-9). The main indications for allogeneic SCT were: ALL/AML in 46% (13/28) and severe aplastic anemia in 21% (6/28). Other indications were chronic granulomatous disease in 4/28, congenital neutropenia in 2/28 and 1/28 each of high-risk neuroblastoma, SCID and transfusion-associated GvHD. Indications for GTs were IFD in 50% (14/28)-proven (n = 4/14), probable (n = 2/14) and possible (n = 8/14) as defined by European Organization for Research and Treatment of Cancer Mycoses Study Group criteria (Pauw et al., 2008). All four patients with proven IFD had Aspergillus spp isolated from the maxillary sinus (n = 1), skin biopsy (n = 2) and bronchoalveolar lavage (n = 1). Bacterial infections were present in 6/28 patients with Pseudomonas spp being the cause in 5/6 cases. Five patients had co-morbidities that were likely to reduce their tolerance to sepsis, that is, cardiomyopathy in 2/5, acute colitis in 2/5 and artificial mitral valve replacement in 1/5. Three out of 28 patients received GTs owing to the possible increased risk to the infection because of previous prolonged neutropenia episodes pretransplant (all three patients received SCT for the relapsed disease and had received 44 courses of the chemotherapy before the SCT). All patients received prophylactic and therapeutic antibacterial and antifungal therapy as per the center's guidelines. Of note, three patients required admission to the intensive care unit at the time of transplant for respiratory support and one of them required inotropic support in addition. The grade of acute mucositis was estimated on the basis of World Health Organization Oral Toxicity score.
Granulocyte donors
All granulocyte donors were volunteers from among the patient's families and friends. In the case of a matched family/sibling donor, we did not use him/her for the GT to avoid sensitization.
1 Donors were medically assessed 
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at the Department of Hematological Medicine, Kings College Hospital, London, UK. Donors were ABO compatible with the patient. CMV-negative recipients were transfused with CMV-negative granulocyte product whenever possible. Some donors were used repeatedly (2-3 times) for donation. All donors were conditioned with G-CSF 5 μg/kg subcutaneously and 8 mg of dexamethasone orally, with harvest performed 12-18 h later using centrifugation apheresis on a continuous flow separator. All granulocyte concentrates were irradiated immediately after the collection and infused within 6-10 h after the collection. No leukocyte compatibility tests were carried out.
RESULTS

Granulocyte transfusions
In total, 145 GTs were administered. GTs were given on alternate days with G-CSF 5 μg/kg given on the off-days starting from D+8 after SCT if ANC was o0.5 × 10 9 /L at that time point. All patients received paracetamol and chlorpheniramine maleate as premedication before the GT. ANC was measured 12-24 h after transfusion. GTs were given until stable and unsupported neutrophil engraftment of 40. Adverse effects There was little toxicity associated with GTs. No adverse effects were observed in 68% (19/28) patients receiving GTs. Fever and mild respiratory symptoms with tachypnea and minimal oxygen requirement were observed in 18% (5/28) and 11% (3/28), respectively. One CMV-negative patient developed transfusionassociated CMV viraemia because a CMV-negative donor was not available. Of note, the patient did not develop signs of CMV disease.
Outcomes
The median follow-up in our cohort of patients is 651 days (7-3841). Overall survival was 64% (18/28) with a mortality rate by D28 was 3.8% (1/28) and mortality rate by D100 was 19.2% (5/28). The data on infection outcomes are summarized in Table 2 . Of the 14 patients with evidence of previous IFD, the majority showed objective radiological improvement or stable disease within 30 days after transplant (7/14 and 6/14 patients, respectively). One patient showed progression of chest fungal lesions and succumbed within 5 days after SCT. In the group with bacterial infections, 3/6 patients died; however, the death was due to progression of sepsis in only one case. Two other patients died due to the disease relapse and CMV pneumonitis (not transfusion transmitted), respectively. None of the patients with co-morbities present before SCT deteriorated after transplant. None of the patients with pre-existing co-morbidies died to the infection or developed infectious complications after SCT. Two of three patients from the heavily pretreated group had succumbed due to unspecified multiorgan failure. Of note, 2/3 patients who required intensive care unit admission at the time of SCT have survived.
The cumulative incidence of grade 2-4 acute mucositis by D100 was 28.6% (8/28). The cumulative incidence of grade 2-4 acute GvHD (aGvHD) by D100 was 17.8% (5/28) and cumulative incidence of grade 3-4 aGVHD by D100 was 7.1% (2/28).
DISCUSSION
The study shows significant benefit of GTs in high-risk pediatric patients undergoing allogeneic SCT. Our patients received a high dose of granulocytes with median dose of 3.56 × 10 10 (range 0.58-8.36) per transfusion, translating into 1.55 × 10 9 /kg (range 0. [3] [4] [5] [6] [7] [8] . This resulted in a good median ANC increment 12-24 h post transfusion, 1.06 × 10 9 /L (range 0-28.8). Clearly, this was easier to achieve in a pediatric as opposed to an adult population. The ANC increment correlated with the granulocyte dose, reported in previous studies, [2] [3] [4] 11, 13, 18 and emphasizes the importance of achieving an optimal granulocyte collection.
The overall survival rate in a high-risk group of patients was 64% (18/28) with a transplant-related mortality rate of 3.8% (1/28) by D28 and 19.2% (5/28) by D100. Although previously published studies showed no benefit of GTs for IFD with mortality remaining high, 6, 7, 12, 19 the majority of our patients with IFD (11/14) have survived. Only 2/10 deaths in our cohort could be attributed to infection progression. Of note, the CMV-negative patient who had transfusion-associated CMV viraemia from CMV-positive donor granulocytes did not develop CMV disease. Nevertheless, the case demonstrates the importance of procurement of CMV-negative granulocytes for CMV-negative recipients.
In our cohort, all patients received premedication before transfusion. We did not observe any significant acute toxicity after GTs. It goes in line with the Cochrane meta-analysis, 16 where adverse events occurred in 15% of patients without premedication as opposed to 0% in premedicated patients. No leukocyte compatibility tests were carried out in our institution. We did not routinely screen for anti-HLA Ab status in our patient cohort.
The finding of low rates of significant grade 3-4 aGvHD was interesting. Only 1/3 of patients experienced grade 3-4 acute mucositis and presumably this was because GTs maintained mucosal integrity, leading to the reduction of bacterial translocation across the intestinal mucosa so reducing serum lipopolysaccharide and TNF production, both of which are integral in generating and triggering aGvHD. 20 We propose that administration of GTs for high-risk pediatric patients undergoing allogeneic SCT is a safe approach and may reduce the risk of mortality from infection. We observed that 2-3 weekly transfusions prevented progression or de novo development of bacterial and fungal infections along with standard antimicrobial treatment. [21] [22] [23] [24] [25] Larger randomized studies are required to confirm the efficacy of prophylactic GTs in such patients and in particular to assess the potential of GTs for reducing aGvHD.
